SLC2A1 and cancer: Nowadays, several GLUT inhibitors such as WZB117, BAY-876, and STF-31, have been preclinically tested, and the results have shown that GLUT inhibition sensitizes cells to anti-cancer treatment, blocks cell growth and glycolysis, and induces apoptosis [151,152,153].